O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications

Journal of Neuro-Oncology

Volumn 101, Issue 3, 2011, Pages 477-486

  Kang, Shin Hyuk ^a   Park, Kyung Jae ^a   Kim, Chae Yong ^e   Yu, Mi Ok ^a,c   Park, Chul Kee ^b   Park, Sung Hye ^d   Chung, Yong Gu ^a  

^a College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Korea University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e NONE

Author keywords

Gliosarcoma; Immunohistochemistry; Methylation specific PCR; O 6 methylguanine DNA methyltransferase

Indexed keywords

ALKYLATING AGENT; GENOMIC DNA; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; DNA; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ANALYSIS; FEMALE; GAMMA KNIFE RADIOSURGERY; GLIOSARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; BRAIN TUMOR; DNA METHYLATION; ENZYME IMMUNOASSAY; GENETICS; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; GLIOSARCOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 79952184256     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0267-9     Document Type: Article

References (43)

1. Salvati M, Caroli E, Raco A, Giangaspero F, Delfini R, Ferrante L (2005) Gliosarcomas: analysis of 11 cases do two subtypes exist? J Neurooncol 74:59-63
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109 (Pubitemid 47103521)
3. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O'Fallon JR, Farr G Jr (1998) Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 89:425-430 (Pubitemid 28405257)
4. Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosarcoma: a clinical study. Radiother Oncol 61:57-64 (Pubitemid 32913462)
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
6. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J (2005) IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65:7573-7579 (Pubitemid 41297227)
7. Brell M, Tortosa A, Verger E, Gil JM, Vinolas N, Villa S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167-5174 (Pubitemid 41003702)
8. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-2399
9. Gonzaga PE, Potter PM, Niu TQ, Yu D, Ludlum DB, Rafferty JA, Margison GP, Brent TP (1992) Identification of the cross-link between human O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA. Cancer Res 52:6052-6058
10. Prados MD, Russo C (1998) Chemotherapy of brain tumors. Semin Surg Oncol 14:88-95 (Pubitemid 128774939)
11. Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, Huynh MB, Kolstoe DD (2002) The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 8:3008-3018 (Pubitemid 35025751)
12. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14:2900-2908
13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
14. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
15. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L, Esteller M (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933-4938 (Pubitemid 39099766)
16. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y (2004) Correlation between promoter hypermethylation of the O6-methylguanine- deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54:349-357; discussion 357
17. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857 (Pubitemid 29001538)
18. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579-584
19. Nakasu S, Fukami T, Baba K, Matsuda M (2004) Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 70:333-340 (Pubitemid 40057961)
20. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324 (Pubitemid 20097526)
21. Meis JM, Martz KL, Nelson JS (1991) Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases. Cancer 67:2342-2349
22. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797 (Pubitemid 29086728)
23. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826 (Pubitemid 26296693)
24. Matsukura S, Miyazaki K, Yakushiji H, Ogawa A, Chen Y, Sekiguchi M (2003) Combined loss of expression of O6-methylguanine-DNA methyltransferase and hMLH1 accelerates progression of hepatocellular carcinoma. J Surg Oncol 82:194-200 (Pubitemid 36278268)
25. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715-1719 (Pubitemid 32952152)
26. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamiya S, Tateishi N, Iwamoto Y, Tsuneyoshi M (2006) DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 19:106-114 (Pubitemid 43250985)
27. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, OhgakiH (2000) Genetic profile of gliosarcomas. Am J Pathol 156:425-432
28. Boerman RH, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-Klein J, Kirchhof A, Raap AK, Scheithauer BW, Jenkins RB (1996) The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J Neuropathol Exp Neurol 55:973-981 (Pubitemid 126449411)
29. di Norcia V, Piccirilli M, Giangaspero F, Salvati M (2008) Gliosarcomas in the elderly: analysis of 7 cases and clinicopathological remarks. Tumori 94:493-496
30. Kim JI, Suh JT, Choi KU, Kang HJ, Shin DH, Lee IS, Moon TY, Kim WT (2009) Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations. Hum Pathol 40:934-941
31. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16:168-174 (Pubitemid 30169152)
32. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC (1998) Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16:3310-3315 (Pubitemid 28481626)
33. Silber JR, Mueller BA, Ewers TG, Berger MS (1993) Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res 53:3416-3420 (Pubitemid 23223319)
34. Tanaka S, Kobayashi I, Utsuki S, Oka H, Fujii K, Watanabe T, Nagashima T, Hori T (2003) O6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 103:67-72 (Pubitemid 35424207)
35. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE II, Walker A, Friedman HS (2009) Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27:1262-1267
36. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE II, Bigner DD, Friedman HS (2002) Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20:2277-2283 (Pubitemid 34441654)
37. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728-2737 (Pubitemid 46795129)
38. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC, Kretzschmar HA (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121:2458-2464 (Pubitemid 350022415)
39. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520-532
40. Blanc JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, Lapierre F, Larsen CJ, Karayan-Tapon L (2004) Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68:275-283 (Pubitemid 38878263)
41. Soejima H, Zhao W, Mukai T (2005) Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol 83:429-437 (Pubitemid 41626761)
42. Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866-875; discussion 875
43. Chen ZP, Yarosh D, Garcia Y, Tampieri D, Mohr G, Malapetsa A, Langleben A, Panasci LC (1999) Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 26:104-109 (Pubitemid 29239161)